These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 7428279)

  • 1. Urine concentration of 3-ethyl-5-hydroxy-4,5-dimethyl-delta 3-pyrrolin-2-one ('mauve factor') is not causally related to schizophrenia or to acute intermittent porphyria.
    Gorchein A
    Clin Sci (Lond); 1980 Jun; 58(6):469-76. PubMed ID: 7428279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation of 3-ethyl-5-hydroxy-4,5-dimethyl-delta 3-pyrrolin-2-one in the urine of patients with acute intermittent porphyria.
    Graham DJ; Brodie MJ; McColl KE; Moore MR; Goldberg A
    Eur J Clin Invest; 1979 Feb; 9(1):49-53. PubMed ID: 110600
    [No Abstract]   [Full Text] [Related]  

  • 3. The 'mauve factor' of schizophrenia and porphyria, 5-hydroxyhaemopyrrole lactam, has low pharmacological potency on guinea-pig ileum.
    Gorchein A; Rogers AT
    Experientia; 1979 Aug; 35(8):1078-9. PubMed ID: 477885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemopyrrole and kryptopyrrole are absent from the urine of schizophrenics and normal persons.
    Gendler PL; Duhan HA; Rapoport H
    Clin Chem; 1978 Feb; 24(2):230-3. PubMed ID: 627053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mauve factor of porphyria, 3-ethyl-5-hydroxy-4,5-dimethyl-delta-3-pyrroline-2-one: effects on behaviour of rats and mice.
    Cutler MG; Graham DJ; Moore MR
    Pharmacol Toxicol; 1990 Jan; 66(1):66-8. PubMed ID: 2308911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative determination of 3-ethyl-5-hydroxy-4,5-dimethyl-delta3-pyrrolin-2-one in urine using gas-liquid chromatography.
    Graham DJ
    Clin Chim Acta; 1978 Apr; 85(2):205-10. PubMed ID: 647980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and biochemical properties of kryptopyrrole and its oxidation products possibly related to acute intermittent porphyria.
    Wetterberg L; Formgren B
    Ann Clin Res; 1976; 8 Suppl 17():162-7. PubMed ID: 1008487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyroluria: Fact or Fiction?
    Warren B; Sarris J; Mulder RT; Rucklidge JJ
    J Altern Complement Med; 2021 May; 27(5):407-415. PubMed ID: 33902305
    [No Abstract]   [Full Text] [Related]  

  • 9. Urinary dipyrrylmethenes in patients with porphyria. A preliminary study of the brown pigments in the urine of a case of acute intermittent porphyria.
    Sears WG; Eales L
    Enzyme; 1974; 17(1):11-6. PubMed ID: 4836422
    [No Abstract]   [Full Text] [Related]  

  • 10. Hydroxy-hemopyrrolenone, not kryptopyrrole, in the urine of schizophrenics and porphyrics.
    Irvine DG
    Clin Chem; 1978 Nov; 24(11):2069-70. PubMed ID: 709853
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hemopyrrollactamuria (HPU); from spots to pseudo-disease].
    van der Meer JW; van de Kerkhof R; The GK; Boers GH
    Ned Tijdschr Geneeskd; 2003 Sep; 147(36):1720-1. PubMed ID: 14520795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excretion of porphobilinogen and 5-aminolaevulinic acid in acute porphyria.
    ACKNER B; COOPER JE; GRAY CH; KELLY M; NICHOLSON DC
    Lancet; 1961 Jun; 1(7189):1256-60. PubMed ID: 13681256
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnosis of a case of acute intermittent porphyria with the aid of thin-layer chromatography-thin-layer electrophoresis of urine.
    Samuels S; Veliz G
    Clin Chem; 1971 Jan; 17(1):51-2. PubMed ID: 5538582
    [No Abstract]   [Full Text] [Related]  

  • 14. Kryptopyrrole-like substance in acute intermittent porphyria.
    Irvine DG; Wetterberg L
    Lancet; 1972 Dec; 2(7788):1201. PubMed ID: 4117628
    [No Abstract]   [Full Text] [Related]  

  • 15. Variegate porphyria.
    Mustajoki P
    Ann Intern Med; 1978 Aug; 89(2):238-44. PubMed ID: 677592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy and the acute porphyrias.
    Brodie MJ; Moore MR; Thompson GG; Goldberg A; Low RA
    Br J Obstet Gynaecol; 1977 Oct; 84(10):726-31. PubMed ID: 921907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [On the excretion of 5-aminolevulinic acid and porphobilinogen in latent porphyria].
    KELENYI G; ARATO G; BUDA V; ORBAN S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1961; 78():205-13. PubMed ID: 14454906
    [No Abstract]   [Full Text] [Related]  

  • 18. [On the problem of treatment of acute intermittent porphyria with ovulation inhibitors. (Studies of delta-aminolevulinic acid, porphobilinogen and total porphyrin excretion)].
    Hocevar V; Rausch-Stroomann JG
    Klin Wochenschr; 1968 Oct; 46(20):1114-6. PubMed ID: 5706556
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.
    Sardh E; Rejkjaer L; Andersson DE; Harper P
    Clin Pharmacokinet; 2007; 46(4):335-49. PubMed ID: 17375984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Best practice guidelines on first-line laboratory testing for porphyria.
    Woolf J; Marsden JT; Degg T; Whatley S; Reed P; Brazil N; Stewart MF; Badminton M
    Ann Clin Biochem; 2017 Mar; 54(2):188-198. PubMed ID: 27555665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.